+

ES2118373T3 - Anticuerpos monoclonales dirigidos contra la proteina tau asociada a microtubulos, hibridomas que segregan estos anticuerpos, reconocimiento de antigenos por estos anticuerpos monoclonales y sus aplicaciones. - Google Patents

Anticuerpos monoclonales dirigidos contra la proteina tau asociada a microtubulos, hibridomas que segregan estos anticuerpos, reconocimiento de antigenos por estos anticuerpos monoclonales y sus aplicaciones.

Info

Publication number
ES2118373T3
ES2118373T3 ES94903752T ES94903752T ES2118373T3 ES 2118373 T3 ES2118373 T3 ES 2118373T3 ES 94903752 T ES94903752 T ES 94903752T ES 94903752 T ES94903752 T ES 94903752T ES 2118373 T3 ES2118373 T3 ES 2118373T3
Authority
ES
Spain
Prior art keywords
monoclonal antibodies
tau protein
pct
antibodies
hybridomes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94903752T
Other languages
English (en)
Inventor
Marc Vandermeeren
Marc Mercken
Eugeen Vanmechelen
De Voorde Andre Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujirebio Europe NV SA
Original Assignee
Innogenetics NV SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogenetics NV SA filed Critical Innogenetics NV SA
Application granted granted Critical
Publication of ES2118373T3 publication Critical patent/ES2118373T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

EL INVENTO SE REFIERE A UN ANTICUERPO MONOCLONAL QUE FORMA UN COMPLEJO INMUNOLOGICO CON UN EPITOPO DE UN ANTIGENO PERTENECIENTE TANTO A UNA PROTEINA TAU HUMANA NORMAL COMO A UNA PROTEINA TAU HUMANA FOSFORILADA ANORMALMENTE, SIENDO POSIBLE OBTENER DICHA PROTEINA TAU DE SER OBTENIDA DE UN CEREBRO HOMOGENEIZADO, HABIENDO SIDO AISLADO ESTE ULTIMO DEL CORTEX CEREBRAL HUMANO. LOS ANTICUERPOS MONOCLONALES DEL INVENTO PUEDEN SER USADOS PARA DETECTAR TAU Y ANORMALMENTE FOSFORILATADO TAU EN EXTRACTOS CEREBRALES Y EN FLUIDO CEREBROESPINAL NO CONCENTRADO.
ES94903752T 1992-12-14 1993-12-10 Anticuerpos monoclonales dirigidos contra la proteina tau asociada a microtubulos, hibridomas que segregan estos anticuerpos, reconocimiento de antigenos por estos anticuerpos monoclonales y sus aplicaciones. Expired - Lifetime ES2118373T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP92403403 1992-12-14

Publications (1)

Publication Number Publication Date
ES2118373T3 true ES2118373T3 (es) 1998-09-16

Family

ID=8211736

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94903752T Expired - Lifetime ES2118373T3 (es) 1992-12-14 1993-12-10 Anticuerpos monoclonales dirigidos contra la proteina tau asociada a microtubulos, hibridomas que segregan estos anticuerpos, reconocimiento de antigenos por estos anticuerpos monoclonales y sus aplicaciones.

Country Status (9)

Country Link
US (1) US5843779A (es)
EP (1) EP0673418B1 (es)
JP (1) JP2879975B2 (es)
AT (1) ATE165866T1 (es)
AU (1) AU690092B2 (es)
DE (1) DE69318420T2 (es)
DK (1) DK0673418T3 (es)
ES (1) ES2118373T3 (es)
WO (1) WO1994013795A1 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811310A (en) * 1986-09-30 1998-09-22 Albert Einstein College Of Medicine Of Yeshiva Univ. The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease
DK0610330T3 (da) * 1991-10-25 1998-01-26 Innogenetics Nv Monoklonale antistoffer mod microtubulus-associeret protein tau
EP0772634B1 (en) * 1994-07-29 2003-03-12 Innogenetics N.V. Monoclonal antibodies specific for an epitope of a particular subclass or form of phosphorylated tau, hybridomas secreting them, antigen recognition of these antibodies and their applications
US6797478B1 (en) * 1998-03-05 2004-09-28 University Of Cincinnati Method of detecting axonal damage, from associated disease states using tau monoclonal antibodies
ATE277353T1 (de) * 1998-09-08 2004-10-15 Innogenetics Nv Tau als marker für frühe schäden des zentralen nervensystems
CA2361013A1 (en) * 1999-01-25 2000-07-27 Minerva Biotechnologies Corporation Rapid and sensitive detection of aberrant protein aggregation in neurodegenerative diseases
EP1216417A1 (de) * 1999-09-28 2002-06-26 Evotec OAI AG Quantitative analyse und typisierung subzellulärer partikel
DE60123752T2 (de) * 2000-01-24 2007-08-23 Innogenetics N.V. Diagnose von tauopathien durch bestimmung des verhältnisses von tau/phospho-tau
US20030162230A1 (en) * 2000-09-27 2003-08-28 Reagan Kevin J. Method for quantifying phosphokinase activity on proteins
WO2004081534A2 (en) * 2003-03-12 2004-09-23 Assay Designs, Inc. Phosphokinase assay
CA2445420A1 (en) 2003-07-29 2005-01-29 Invitrogen Corporation Kinase and phosphatase assays
US7619059B2 (en) 2003-07-29 2009-11-17 Life Technologies Corporation Bimolecular optical probes
US7727752B2 (en) 2003-07-29 2010-06-01 Life Technologies Corporation Kinase and phosphatase assays
US7238788B2 (en) * 2004-02-18 2007-07-03 University Of Iowa Foundation Antibodies to phosphorylated tau, methods of making and methods of use
US20070178447A1 (en) * 2006-01-31 2007-08-02 Bethyl Laboratories, Inc. Method for decreasing interference in results of immunochemical methods
WO2010106127A2 (en) * 2009-03-18 2010-09-23 Ac Immune S.A. Method for therapeutic use
UA107571C2 (xx) * 2009-04-03 2015-01-26 Фармацевтична композиція
US8940272B2 (en) 2010-10-11 2015-01-27 University Of Zurich Human anti-tau antibodies
GB201111361D0 (en) * 2011-07-04 2011-08-17 Nordic Bioscience As Biochemical markers for neurodegenerative conditions
KR102132041B1 (ko) 2012-04-05 2020-07-09 에이씨 이뮨 에스.에이. 인간화된 타우 항체
ES2775192T3 (es) 2012-08-16 2020-07-24 Ipierian Inc Procedimientos de tratamiento de una tauopatía
US9200068B2 (en) 2012-12-18 2015-12-01 Regents Of The University Of Minnesota Compositions and methods related to tauopathy
EP3792278A3 (en) 2012-12-21 2021-05-26 Biogen MA Inc. Human anti-tau antibodies
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
CA2902026C (en) 2013-03-13 2023-08-29 Prothena Biosciences Limited Tau immunotherapy
EP2970452A2 (en) 2013-03-15 2016-01-20 AC Immune S.A. Anti-tau antibodies and methods of use
WO2015122922A1 (en) 2014-02-14 2015-08-20 Ipierian, Inc. Tau peptides, anti-tau antibodies, and methods of use thereof
FI3452507T3 (fi) 2016-05-02 2022-12-15 Tau-immuunihoito
IL262726B2 (en) 2016-05-02 2024-07-01 Prothena Biosciences Ltd Antibodies recognizing tau
MX2019013045A (es) 2017-05-02 2020-02-12 Prothena Biosciences Ltd Anticuerpos que reconocen tau.
TWI827557B (zh) 2017-10-25 2024-01-01 美商健生醫藥公司 Ｔａｕ胜肽之組成物及其用途
US20220018856A1 (en) 2018-11-22 2022-01-20 Fujirebio Inc. Antibody conjugate
PH12021551876A1 (en) 2019-02-08 2022-05-23 Ac Immune Sa Method of safe administration of phosphorylated tau peptide vaccine
CN113544149B (zh) 2019-03-03 2024-11-15 普罗塞纳生物科学有限公司 识别tau的抗体
CA3137884A1 (en) 2019-04-24 2020-10-29 Janssen Pharmaceuticals, Inc. Heterologous administration of tau vaccines
US20220365102A1 (en) * 2019-09-30 2022-11-17 Nipro Corporation Tau protein detection method using blood sample as test specimen
AU2021257848A1 (en) 2020-04-15 2022-12-01 Voyager Therapeutics, Inc. Tau binding compounds
CN111349617B (zh) * 2020-05-25 2020-09-22 苏州仁端生物医药科技有限公司 一种分泌抗Tau或pTau-181/231/396单克隆抗体杂交瘤细胞株及其应用
MX2023007181A (es) 2020-12-16 2023-08-30 Voyager Therapeutics Inc Compuestos de union a tau.
EP4271708A1 (en) 2020-12-29 2023-11-08 Neurimmune AG Human anti-tau antibodies
CN113005096B (zh) * 2021-01-19 2022-10-14 华中科技大学 分泌抗丝氨酸磷酸化tau蛋白单克隆抗体的杂交瘤细胞株
CN114539400B (zh) * 2022-02-15 2024-06-07 武汉天德生物科技有限公司 一种磷酸化Tau pT217蛋白单克隆抗体、ELISA试剂盒及其应用
WO2023250388A1 (en) 2022-06-22 2023-12-28 Voyager Therapeutics, Inc. Tau binding compounds
IL319121A (en) 2022-09-15 2025-04-01 Voyager Therapeutics Inc Tau-binding compounds

Also Published As

Publication number Publication date
AU5809794A (en) 1994-07-04
AU690092B2 (en) 1998-04-23
DE69318420D1 (de) 1998-06-10
EP0673418B1 (en) 1998-05-06
DK0673418T3 (da) 1999-03-01
US5843779A (en) 1998-12-01
ATE165866T1 (de) 1998-05-15
DE69318420T2 (de) 1999-01-28
JPH08502898A (ja) 1996-04-02
EP0673418A1 (en) 1995-09-27
WO1994013795A1 (en) 1994-06-23
JP2879975B2 (ja) 1999-04-05

Similar Documents

Publication Publication Date Title
ES2118373T3 (es) Anticuerpos monoclonales dirigidos contra la proteina tau asociada a microtubulos, hibridomas que segregan estos anticuerpos, reconocimiento de antigenos por estos anticuerpos monoclonales y sus aplicaciones.
DK0610330T3 (da) Monoklonale antistoffer mod microtubulus-associeret protein tau
ATE302411T1 (de) Diagnose, prophylaxe und behandlung von morbus crohn durch die verwendung des ompc antigens
FI970301A0 (fi) Spesifisen immunoglobuliinin määrittäminen käyttäen useampaa antigeenia
DK0616537T3 (da) CDw52-specifikt antistof til behandling af dissemineret sclerose
ATE233814T1 (de) Humaner neutralisierender monoklonaler antikörper gegen den die immunschwäche beim menschen hervorringenden virus
DE69433663D1 (de) Antikörper gegen menschliches prostatspezifisches drüsenkallikrein
ATE234324T1 (de) Monoklonale antikörper gegen ein epitop einer gewissen unterklasse oder form von phosphoryliertem tau, hybridome die diese sezernieren,antigenerkennung durch diese antikörper und deren verwendung
BG102541A (en) Diagnostics and mediators of inflammatory processes
DK0741870T3 (da) Fremgangsmåde til kvantificering af LBP i kropsvæsker
ATE202116T1 (de) Antikörperklassenspezifisches entstörungsreagenz
ES2109242T3 (es) Anticuerpos monoclonales contra inmunoglobulina e humana.
Son et al. Detection and characterization of excretory/secretory proteins from Toxoplasma gondii by monoclonal antibodies
NO972522L (no) Monoklonale antistoffer med immunoundertrykkende aktivitet
MX9601930A (es) Anticuerpos anti-idiotipicos los cuales inducen una respuesta inmune contra el receptor de crecimiento epidermico.
DK0720745T3 (da) Fremgangsmåde til kvantificering af ekstracellulært BPI i legemsvæsker
ES2061664T3 (es) Anticuerpos monoclonales que reconocen a alfa-hanp y correspondientes hibridomas, su preparacion y uso.
ES2090331T3 (es) Ctaa 28a32, antigeno reconocido por mca 28a32.
DK329789A (da) Monoklonalt antistof
BR0307308A (pt) Antìgenos de superfìcies larvais nematóides
ES2082040T3 (es) Anticuerpos monoclonales que reconocen a la fosfolipasa a2 de membrana e inmunoensayos de fosfolipasa a2 de membrana.
ES2107545T3 (es) Anticuerpos policlonales dirigidos contra la hirudina y su utilizacion para la identificacion, la purificacion inmunologica y la determinacion cuantitativa de la hirudina.
ATE281471T1 (de) Antikörper-testbesteck zur bestimmung von amylin
ECSP951605A (es) Fragmentos de anticuerpos monoclonales que tienen actividad inmunosupresora, case ran 4105/171
Masat et al. Loss of the β1 subunit of the sodium pump during lymphocyte differentiation

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 673418

Country of ref document: ES

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载